BRPI0821455A2 - Composições farmacêuticas de amlopidina e valsartan - Google Patents

Composições farmacêuticas de amlopidina e valsartan

Info

Publication number
BRPI0821455A2
BRPI0821455A2 BRPI0821455-7A BRPI0821455A BRPI0821455A2 BR PI0821455 A2 BRPI0821455 A2 BR PI0821455A2 BR PI0821455 A BRPI0821455 A BR PI0821455A BR PI0821455 A2 BRPI0821455 A2 BR PI0821455A2
Authority
BR
Brazil
Prior art keywords
amlopidine
pharmaceutical compositions
valsartan pharmaceutical
valsartan
compositions
Prior art date
Application number
BRPI0821455-7A
Other languages
English (en)
Inventor
Anirudha Bhagirath Kute E Outros
Nikhil Prabhakar Malewar
Makarand Krishnajkumar Avachat
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BRPI0821455A2 publication Critical patent/BRPI0821455A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0821455-7A 2007-12-31 2008-02-21 Composições farmacêuticas de amlopidina e valsartan BRPI0821455A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1449KO2007 2007-12-31
PCT/IN2008/000103 WO2009084003A1 (en) 2007-12-31 2008-02-21 Pharmaceutical compositions of amlodipine and valsartan

Publications (1)

Publication Number Publication Date
BRPI0821455A2 true BRPI0821455A2 (pt) 2015-06-16

Family

ID=39739299

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821455-7A BRPI0821455A2 (pt) 2007-12-31 2008-02-21 Composições farmacêuticas de amlopidina e valsartan

Country Status (8)

Country Link
US (1) US8785432B2 (pt)
EP (1) EP2240163A1 (pt)
JP (1) JP2011507973A (pt)
AU (1) AU2008344891A1 (pt)
BR (1) BRPI0821455A2 (pt)
MX (1) MX2010007281A (pt)
WO (1) WO2009084003A1 (pt)
ZA (1) ZA201005442B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
WO2013100112A1 (ja) * 2011-12-28 2013-07-04 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
WO2014038895A1 (ko) * 2012-09-06 2014-03-13 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
PL3320903T3 (pl) * 2015-07-08 2021-12-06 Hk Inno.N Corporation Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę
WO2019135691A1 (en) * 2018-01-04 2019-07-11 Jamjoom Pharmaceuticals Factory Company Limited A stable mono-layer solid dosage form containing combination of two active ingredients
CN109010338B (zh) * 2018-09-13 2021-09-21 合肥合源药业有限公司 一种缬沙坦氨氯地平片的制备方法及缬沙坦氨氯地平片
CN109394712B (zh) * 2018-11-23 2019-11-12 海南妙音春制药有限公司 一种缬沙坦氨氯地平复方片剂及其制备方法
CN112641743B (zh) * 2020-12-23 2022-09-02 上海耀大生物科技有限公司 一种用于治疗高血压的复方制剂及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4879903A (en) * 1988-09-02 1989-11-14 Nova Sensor Three part low cost sensor housing
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
TR200100062T2 (tr) * 1998-07-10 2001-06-21 Novartis Ag Valsartan ve kalsiyum kanalı bloklayıcısının anti-hipertensif kombinasyonu
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0601405D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
AU2008344891A1 (en) 2009-07-09
ZA201005442B (en) 2011-04-28
MX2010007281A (es) 2010-10-05
JP2011507973A (ja) 2011-03-10
US8785432B2 (en) 2014-07-22
WO2009084003A1 (en) 2009-07-09
US20100272801A1 (en) 2010-10-28
EP2240163A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
LTPA2018014I1 (lt) Farmacinė kompozicija 514
LTPA2018005I1 (lt) Farmacinė kompozicija
BRPI0715712A2 (pt) Composição farmacêutica
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0721651A2 (pt) Composição farmacêutica
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
IL200885A (en) A history of mannich-based compounds and pharmacological preparations including them
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
DK2120884T3 (da) Farmaceutisk sammensætning
EP2154966A4 (en) BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
BRPI0908132A2 (pt) Composto de benzodiazepina e composição farmacêutica
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
BRPI0817833A2 (pt) Composição farmacêutica antimalárica
BRPI0821455A2 (pt) Composições farmacêuticas de amlopidina e valsartan
BRPI0820198A2 (pt) composições farmacêuticas
IL201894A (en) A quinolone compound and a @pharmaceutical containing @
BRPI0807903A2 (pt) Composições medicinais melhoradas compreendendo buprenorfina e nalmefeno.
DK2271321T3 (da) Farmaceutisk sammensætning 271
BRPI0912074A2 (pt) composto e composição farmacêutica
GB0614365D0 (en) Pharmaceutical compositions and their use
DK2231603T3 (da) Substituerede 3-hydroxypyridiner og farmaceutiske sammensætninger deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.